reference/27511473

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27511473

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	558
issn	0344-5704 1432-0843
issueIdentifier	4
pageRange	549-558
publicationName	Cancer Chemotherapy and Pharmacology
startingPage	549
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b5e33e88b94f54dd14fcd4a52f582ca7 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5a398735b44ce0a0606efb6fbb207ba3
bibliographicCitation	Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr;61(4):549–58. doi: 10.1007/s00280-007-0500-1. PMID: 17522864.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c17f9f7a806c60055ae328dd4b03eeaf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7375ec4b53d32a4b6f612a94789db348 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9677ee0d6557799e801e1b020e63d813 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d4ee6122d337a886d207b32318b6044d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd6d164b52eb10c7fb5e62fca4a24ccb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54641963dfcb8410d29dc4d535f9f0cb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d436714a0168b28418c18ea736c30e5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_81cef9a567c81b593ddce1e28589f9aa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_184cc43696877eb67afe17cadac09302
date	2007-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1007/s00280-007-0500-1 https://pubmed.ncbi.nlm.nih.gov/17522864
isPartOf	https://portal.issn.org/resource/ISSN/1432-0843 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2664 https://portal.issn.org/resource/ISSN/0344-5704
language	English
source	https://www.crossref.org/ https://scigraph.springernature.com/ https://pubmed.ncbi.nlm.nih.gov/
title	Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
discusses	http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0004505 http://id.nlm.nih.gov/mesh/M0560885 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0002834 http://id.nlm.nih.gov/mesh/M0014578 http://id.nlm.nih.gov/mesh/M0018225 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0350110
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_00018f81c30c51bce348eb37edf93cc0 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.25.1 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_6600c5cd2493e3a8f413e3b3388d00c7 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9c79da2a86f6c595a38b838a7a321b92 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cda04602609c8ff643bfe58ca4aa6a09 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c2b3a5ba99bc94e77229bab735b7776f http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_2c7bb8c933bedf612fa484b24eb8abd1 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7826c784e8fc911de47e7fb31a96992f http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6761 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b8b61580f3b0744d9098586a01c34cc3 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b30b0b608593935259123d48ab1a931d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8366 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID387447 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_42e5c8717e13ca9e92807498eccbf953

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243055978

Total number of triples: 63.